15.03
-0.07%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tibet Aim Pharm
Its shares trade on Shenzhen under the ticker 002826.SZ. It has been listed since 9 December 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥636.3m and net income of CN¥92.6m. At that date it held total assets of CN¥1.02bn and shareholders' equity of CN¥816.0m.
Tibet Aim Pharm., Inc. engages in the research and development, production, and sale of chemical drugs, and Chinese medicines. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2016-12-09. The Company’s products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Dec 2016
- Employees
- 447
- Website
- emyy.cn ↗
Leadership
Pay as last reported
- Ms. Lihua FuChairman of the Board, since 2025
- Mr. Ke XuChief Financial Officer, General Manager, since 2015
- Ms. Lingyi HuangDirector
- Ms. Ling LiStaff Elected Director
- Ms. Yan YaoDirector
- Ms. Yan ChenIndependent Director
- Mr. Deming HeIndependent Director
- Mr. Guangying WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tibet Aim Pharm Inc employs 447 full-time employees in Chengdu, Sichuan.
- Tibet Aim Pharm Inc produces miglitol tablets, hongjinxiaojie tablet, and aceclofenac enteric-coated tablets.
- Tibet Aim Pharm Inc distributes self-manufacturing medicine and third-party medicine in domestic and overseas markets.
Weaknesses
- Tibet Aim Pharm Inc's products include domperidone tablets and montmorillonite powder.
- Tibet Aim Pharm Inc's third-party medicine includes gualoupi injection and nalmefene hydrochloride injection.
- Tibet Aim Pharm Inc's IPO was on 9 December 2016, which may limit growth opportunities.
Opportunities
- Tibet Aim Pharm Inc's self-manufacturing medicine includes carbetocin injection and cefotaxime sodium for injection.
- Tibet Aim Pharm Inc's products target domestic and overseas markets for expansion.
- Tibet Aim Pharm Inc's industry is Pharmaceuticals within Health Care sector.
Threats
- Tibet Aim Pharm Inc's third-party medicine includes oral liquid for children and cefotaxime sodium for injection.
- Tibet Aim Pharm Inc's products are limited to chemical drugs and Chinese medicines.
- Tibet Aim Pharm Inc's headquarters is in Chengdu, Sichuan, which may restrict market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.